Incidence and Outcomes of Atrial Fibrillation and Systolic Dysfunction in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: A Multicenter Study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nguyen Olives, Wiedrick Jack, Massera Daniele, Adlestein Elizabeth, Frejat Sumar, Castrichini Matteo, Alsidawi Said, Giudicessi John R, Geske Jeffrey B, Carrick Richard T, Madrazo Jose, Dellise Nicole, Zenker Mark A, Boyle Thomas A, Reza Nosheen, Owens Anjali Tiku, Frankel David S, Hundal Prabhjot, Tajik Jamil, Galazka Patrycja, Lewontin Myra, Ayers Michael, Wong Timothy, Flanagan Michael, Mitter Sumeet Singh, Kanwal Arjun, Bilen Ozlem, Baghdadi Sarah, Shah Hirak, Kvapil Jared, Roldan Paola, Berenbom Loren, Jesurum Jill, Tootill Denise, Siqueira-Benzow Alice, Harper Mariko, Saleh Danish, Choudhury Lubna, Valenta Isabela, Lang Melissa, Phelan Dermot M, Prizand Dmitry, Lakdawala Neal, Ho Carolyn Y, Liang Lusha W, Weiner Shepard D, Ravi Sririam, Abuzaid Ahmed Sami, Makkiya Mohammed, Markowitz Jeremy S, Sherrid Mark, Masri Ahmad
Аннотация
OBJECTIVE: Determine the real-world incidence of new-onset and recurrent AF among patients with HCM treated with commercial mavacamten. Secondary objectives included assessing the incidences of LVSD, heart failure (HF), and cardiogenic shock.
DESIGN: A multicenter cohort study. Center-level data were aggregated for patients who received mavacamten from May 2022 through December 2024.
SETTING: Twenty-one outpatient HCM centers in the United States.
PARTICIPANTS: Consecutive patients ≥18 years of age with oHCM were included; those with permanent AF were excluded.
EXPOSURES: At least one dose of commercial mavacamten.
MAIN OUTCOMES AND MEASURES: Incidence of new-onset and recurrent AF, LVSD, HF, and cardiogenic shock.
RESULTS: Among 1,538 patients (median age, 66 years [95% CI, 65.9-66.1]; 57% female [95% CI, 54-59%]), 25% [95% CI, 22-27%] had prior AF. Median mavacamten exposure was 13.4 months [95% CI, 11.8-15.0]. Overall AF incidence was 13% [95% CI, 10-17%], including 5% [95% CI, 4-7%] new-onset and 39% [95% CI, 27-51%] recurrent AF in those with history of AF prior to mavacamten initiation. LVEF <50% occurred in 8% [95% CI, 6-9%], of whom 70% had AF. Symptomatic HF occurred in 1.5% [95% CI, 0.8-2.2%], cardiogenic shock in 0.6% [95% CI, 0.1-1.0%], and an overall permanent discontinuation of mavacamten in 7% [95% CI, 4-10%].
CONCLUSIONS AND RELEVANCE: In this multicenter cohort receiving commercial mavacamten, we identified an annual incidence of 5% new-onset AF and 39% recurrent AF, while 70% of patients who developed LVEF<50% had concurrent AF. Given this association and the morbidity that can be associated with AF, protocols for LVEF assessment and aggressive rhythm management following AF detection may be warranted to improve patient care. Further studies are needed to improve understanding of the impact of mavacamten on AF and patient outcomes.